European Journal of Clinical Pharmacology

Papers
(The H4-Index of European Journal of Clinical Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-04-01 to 2026-04-01.)
ArticleCitations
Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia156
Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study67
Understanding attitudes towards psychiatric medications: a comparative study of patients, healthcare professionals, and general population perspectives58
Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis42
Anticholinergic burden and cognitive performance: cross-sectional results from the ELSA-Brasil study41
Might chronic spontaneous urticaria develop after SARS-CoV-2 vaccinations?35
Identification of novel signal of DRESS associated with antibiotics: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database33
Oral Melatonin for Pain Relief During Venepuncture in Neonates– a Pilot Randomized Control Trial33
Lowering cyclosporine trough concentration threshold effectively mitigates acute graft-versus-host disease in children with severe β-Thalassemia post hematopoietic stem cell transplantation32
Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis32
Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy29
How to make the best of NLRP3 inhibitors in patients with COVID-19?28
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors27
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease27
A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress27
Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study26
Correction to: A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals24
Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics24
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials24
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis23
Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia21
Clinical pharmacology—how it shapes the drug development journey21
Comment on “Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank”21
0.17810106277466